Intellia Therapeutics (NASDAQ:NTLA) Receives “Neutral” Rating from Wedbush

Wedbush reaffirmed their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report report published on Thursday,RTT News reports. They currently have a $14.00 price objective on the stock.

A number of other analysts also recently weighed in on NTLA. The Goldman Sachs Group reduced their target price on shares of Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Citigroup lowered their price target on shares of Intellia Therapeutics from $25.00 to $19.00 and set a “neutral” rating for the company in a research report on Friday, October 25th. Stifel Nicolaus decreased their target price on shares of Intellia Therapeutics from $80.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday, September 11th. Robert W. Baird cut their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a research note on Friday, October 25th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $54.00 price target on shares of Intellia Therapeutics in a research note on Thursday, September 19th. One research analyst has rated the stock with a sell rating, five have assigned a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $58.13.

Intellia Therapeutics Stock Performance

Shares of Intellia Therapeutics stock traded up $0.43 on Thursday, hitting $16.43. 1,021,412 shares of the company’s stock were exchanged, compared to its average volume of 1,653,865. The company has a 50-day simple moving average of $19.28 and a 200-day simple moving average of $22.25. The stock has a market capitalization of $1.67 billion, a PE ratio of -2.92 and a beta of 1.81. Intellia Therapeutics has a 1 year low of $13.95 and a 1 year high of $34.87.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The firm had revenue of $9.10 million for the quarter, compared to analysts’ expectations of $8.28 million. The firm’s quarterly revenue was down 24.1% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.38) EPS. On average, analysts expect that Intellia Therapeutics will post -5.21 EPS for the current fiscal year.

Insider Buying and Selling

In related news, CAO Michael P. Dube sold 2,012 shares of the stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the sale, the chief accounting officer now directly owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 3.20% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

A number of hedge funds have recently added to or reduced their stakes in NTLA. LMR Partners LLP lifted its holdings in Intellia Therapeutics by 35.3% during the third quarter. LMR Partners LLP now owns 71,100 shares of the company’s stock valued at $1,461,000 after purchasing an additional 18,533 shares in the last quarter. Quest Partners LLC lifted its holdings in Intellia Therapeutics by 181.6% during the third quarter. Quest Partners LLC now owns 19,748 shares of the company’s stock valued at $406,000 after purchasing an additional 12,734 shares in the last quarter. Curi RMB Capital LLC lifted its holdings in Intellia Therapeutics by 13.5% during the third quarter. Curi RMB Capital LLC now owns 39,187 shares of the company’s stock valued at $805,000 after purchasing an additional 4,662 shares in the last quarter. KBC Group NV lifted its holdings in Intellia Therapeutics by 37.3% during the third quarter. KBC Group NV now owns 3,753 shares of the company’s stock valued at $77,000 after purchasing an additional 1,020 shares in the last quarter. Finally, Axxcess Wealth Management LLC lifted its holdings in Intellia Therapeutics by 5.4% during the third quarter. Axxcess Wealth Management LLC now owns 20,215 shares of the company’s stock valued at $415,000 after purchasing an additional 1,044 shares in the last quarter. 88.77% of the stock is owned by hedge funds and other institutional investors.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.